The Centers for Medicare and Medicaid Services (CMS) and pharmaceutical drug manufacturers are gearing up for the second ...

Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...

Type 2 diabetes and obesity are intimately linked; reduction of bodyweight improves glycemic control, mortality and morbidity. Treating obesity in the diabetic is hampered as some diabetic ...

Ozempic/Wegovy is the first drug on HHS's 2025 list of Medicare price negotiations. As the leaders of the pharmaceutical industry boarded their planes to come home from the JP Morgan Healthcare ...

Increasing interest in real-world evidence (RWE) across all stakeholder groups has the industry buzzing about its current role in clinical trials and the potential impact of expanded use.

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.